Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis
Future research will determine whether GLP-1 drugs can become a mainstay in treating neurological and psychiatric conditions alongside traditional therapies
Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systemic review and meta-analysis with trial sequential analysis
The technique is identical to Semaglutide
Abbreviations CVD: Cardiovascular disease T2D: Type 2 diabetes CV: Cardiovascular HF: Heart failure GLP-1RA: Glucagon-like peptide 1 receptor agonist SGLT-2: Sodium-glucose cotransporter 2 MACE: Major cardiovascular events MI: Myocardial infarction ADA: American Diabetes Association HFrEF: Heart failure with reduced ejection fraction HFpEF: Heart failure with preserved ejection fraction FDA: Food and Drug Administration NHANES: National Health and Nutrition Examination Survey CKD: Chronic kidney disease References Grundy SM, Benjamin IJ, Burke GL, et al
Critical preclinical studies in animals Building on this foundation, many drugs were developed targeting this pathway, such as liraglutide and semaglutide (including Ozempic and Wegovy) helping millions of people manage diabetes and achieve healthy weight loss
